T Bschleipfer1, M Burkart2. 1. Klinik für Urologie, Andrologie und Kinderurologie, Klinikum Weiden/Kliniken Nordoberpfalz AG, Söllnerstraße 16, 92637, Weiden i.d.OPf., Deutschland. thomas.bschleipfer@kliniken-nordoberpfalz.ag. 2. Dr. Willmar Schwabe GmbH & Co. KG, Betriebsstätte Ettlingen, Bunsenstraße 6-10, 76275, Ettlingen, Deutschland.
Abstract
BACKGROUND: Benign prostate syndrome is frequently associated with sexual dysfunction. The therapeutic options discussed in the S2e guideline may be able to improve existing sexual dysfunctions but can also worsen disorders or even trigger new ones. OBJECTIVES: What are the effects of therapeutic options as described in the S2e guideline on sexual function? METHODS: By selective literature search related to benign prostate syndrome and sexual dysfunction adverse effects of drugs mentioned in the S2e guideline have been evaluated. RESULTS: Serenoa repens extracts do not have adverse effects on sexual function; this is also true for muscarine receptor antagonists. 5α-Reductase inhibitors frequently worsen erectile function, libido and ejaculation; selective α1-blockers have an adverse effect on ejaculation. Phosphodiesterase (PDE)-5 inhibitors can improve sexual function. A combination of α1-blockers and 5α-reductase inhibitors worsens sexual functions significantly. CONCLUSIONS: A suitable therapy for benign prostate syndrome should be chosen jointly by the patient and the treating physician and should be adapted to personal needs. Effects on sexual functions have to be taken into consideration when choosing a therapy.
BACKGROUND:Benign prostate syndrome is frequently associated with sexual dysfunction. The therapeutic options discussed in the S2e guideline may be able to improve existing sexual dysfunctions but can also worsen disorders or even trigger new ones. OBJECTIVES: What are the effects of therapeutic options as described in the S2e guideline on sexual function? METHODS: By selective literature search related to benign prostate syndrome and sexual dysfunction adverse effects of drugs mentioned in the S2e guideline have been evaluated. RESULTS:Serenoa repens extracts do not have adverse effects on sexual function; this is also true for muscarine receptor antagonists. 5α-Reductase inhibitors frequently worsen erectile function, libido and ejaculation; selective α1-blockers have an adverse effect on ejaculation. Phosphodiesterase (PDE)-5 inhibitors can improve sexual function. A combination of α1-blockers and 5α-reductase inhibitors worsens sexual functions significantly. CONCLUSIONS: A suitable therapy for benign prostate syndrome should be chosen jointly by the patient and the treating physician and should be adapted to personal needs. Effects on sexual functions have to be taken into consideration when choosing a therapy.
Entities:
Keywords:
Benign prostate syndrome; Drug therapy; Ejaculation; Erectile dysfunction; Libido
Authors: Mauro Gacci; Giovanni Corona; Matteo Salvi; Linda Vignozzi; Kevin T McVary; Steven A Kaplan; Claus G Roehrborn; Sergio Serni; Vincenzo Mirone; Marco Carini; Mario Maggi Journal: Eur Urol Date: 2012-02-25 Impact factor: 20.096
Authors: Adolfo Casabé; Claus G Roehrborn; Luigi F Da Pozzo; Sebastian Zepeda; R Jonathan Henderson; Sebastian Sorsaburu; Carsten Henneges; David G Wong; Lars Viktrup Journal: J Urol Date: 2013-10-02 Impact factor: 7.450
Authors: François Giuliano; Matthias Oelke; Andreas Jungwirth; Konstantinos Hatzimouratidis; Steven Watts; David Cox; Lars Viktrup Journal: J Sex Med Date: 2013-01-24 Impact factor: 3.802
Authors: Tina Kiguradze; William H Temps; Steven M Belknap; Paul R Yarnold; John Cashy; Robert E Brannigan; Beatrice Nardone; Giuseppe Micali; Dennis Paul West Journal: PeerJ Date: 2017-03-09 Impact factor: 2.984